Navigate Up
UPMC/University of Pittsburgh Schools of the Health Sciences
Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.

University of Pittsburgh Researcher Provides First-Ever Definition of HIV-Associated Lipodystrophy

PITTSBURGH, July 19, 2001 — An AIDS researcher from the University of Pittsburgh Graduate School of Public Health (GSPH) today proposed the first definition of HIV-associated lipodystrophy syndrome (HIV-LS)-- the set of physical and metabolic changes that many individuals develop primarily while on HIV drug therapy.

Lawrence Kingsley, Dr. P.H., proposed the definition in Chicago at the 2001 Sessions of the International Association of Physicians in AIDS Care (IAPAC).

"Because there has been no formal definition of the HIV-associated lipodystrophy syndrome up to this point, the prevalence of reported cases of this condition have varied widely -- from less than 10 percent of HIV-infected persons to more than 80 percent," noted Dr. Kingsley, associate professor of infectious diseases and epidemiology at the University of Pittsburgh GSPH. "We are proposing a description of the syndrome that can guide physicians and other health care providers in properly diagnosing their patients."

HIV-LS involves changes in fat distribution throughout the body, along with cholesterol and glucose abnormalities, in HIV-infected individuals taking highly-active antiretroviral therapy (HAART) or antiretroviral therapy (ART), and in some people who are not on drug therapy but who have long-term HIV infection. The body-shape changes experienced by patients are dramatic and anxiety provoking, while the changes in lipids and glucose metabolism may increase their long-term risk of cardiovascular disease.

Signs of HIV-LS are a wasting, or a reduction in fat (lipoatrophy), in the face, arms, legs and buttocks; and an increase in fat (lipodystrophy) in the abdomen, back of the neck and breasts. The added abdominal fat is primarily visceral fat, which accumulates within the abdominal cavity, around the organs.

Dr. Kingsley's proposed definition of HIV-LS follows:

Peripheral Lipoatrophy only -- moderate or greater subcutaneous fat loss in two or more of the following areas: arms, legs, buttocks or face scored as mild, moderate or severe.

"Mixed" Lipodystrophy -- peripheral lipoatrophy (see 1. above) plus moderate or greater increased fat accumulation in the abdomen or breasts, with or without additional fat at the back of the neck.

Peripheral Lipoatrophy or Mixed Lipodystrophy along with metabolic abnormalities of glucose metabolism or lipids.

In monitoring HIV-infected individuals every three to six months, Dr. Kingsley suggests that health care providers keep track of changes in height, weight, body-mass index, arm, thigh, waist, hip and waist-to-hip ratio using the standardized protocol.

Dr. Kingsley recommends dual energy X-ray absorptiometry (DEXA) scan for quantifying muscle, bone and fat in arms, legs and abdomen, and computed tomography (CT) or MRI to quantify and discriminate between visceral and subcutaneous fat.

In addition, Dr. Kingsley recommends the following fasting blood tests for metabolic abnormalities: cholesterol (total, HDL and LDL), triglycerides, HBA1c, glucose, insulin, apolipoprotein A and B, and lipoprotein A.

Dr. Kingsley's recommendations are based on clinical information gathered through the Multicenter AIDS Cohort Study (MACS), a National Institutes of Health-funded epidemiological study of HIV infection in homosexual men. The University of Pittsburgh GSPH is one of four sites nationwide participating in the MACS. Dr. Kingsley is co-principal investigator of the Pittsburgh-site, known locally as the Pitt Men's Study. MACS is currently in its 16th year of surveying the natural history of HIV.

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com